In a previous comparison of antagonised benzodiazepine anaesthesia I against a total intravenous technique using propofol, we found that following reversal an impairment in psychomotor performance persisted in the antagonised benzodiazepine group for approximately four hours. Patients in this group, however, had also received fentanyl, nitrous oxide and isoflurane for maintenance of anaesthesia. Although it is possible that the Accepted for publication February 27, 1989 psychomotor impairment represented the residual effects of these agents we considered it more likely that the dose of flumazenil was insufficient to reverse the midazolam component (mean dose ofmidazolam used 17 mg with flumazenil 1.0 mg given at a mean of 14 minutes from induction). A similar result was found by Raeder et aU who used flumazenil 0.5 mg following a technique incorporating midazolam 0.3 mg/kg. In addition a recent paper examining diazepaminduced ventilatory depression found incomplete reversal of the ventilatory depression following flumazenil 1.0 mg.
Flumazenil is an imidazo-benzodiazepine which competitively antagonises benzodiazepine action at the GABA A receptor. Although adenosine antagonists such as caffeine and aminophylline are capable of antagonising some benzodiazepine actions, flumazenil represents the first clinically reliable method of reversal.
In a previous comparison of antagonised benzodiazepine anaesthesia I against a total intravenous technique using propofol, we found that following reversal an impairment in psychomotor performance persisted in the antagonised benzodiazepine group for approximately four hours. Patients in this group, however, had also received fentanyl, nitrous oxide and isoflurane for maintenance of anaesthesia. Although it is possible that the psychomotor impairment represented the residual effects of these agents we considered it more likely that the dose of flumazenil was insufficient to reverse the midazolam component (mean dose ofmidazolam used 17 mg with flumazenil 1.0 mg given at a mean of 14 minutes from induction). A similar result was found by Raeder et aU who used flumazenil 0.5 mg following a technique incorporating midazolam 0.3 mg/kg. In addition a recent paper examining diazepaminduced ventilatory depression found incomplete reversal of the ventilatory depression following flumazenil 1.0 mg. 3 In this study we examine the ability of intravenous flumazenil 1.0 mg or 4.0 mg to antagonise the psychomotor effects of intravenous midazolam 10 mg in volunteers. METHODS The study was performed on six male volunteers aged 25 to 35 years. Their mean age was 27 (SD 3) years, weight 85 (SD 18) kilograms and height 183 (SD 10) centimeters. All were healthy, on no psychotropic medication and had refrained from alcohol for 24 hours and caffeine-containing beverages for 12 hours prior to each study period. Local ethical committee approval was obtained before commencing the study and informed consent was obtained from each volunteer.
On each of the three study days an 18 gauge intravenous cannula was inserted into the non-dominant forearm. According to a random order, crossover design the volunteers received either (a) midazolam 10 mg followed after ten minutes by flumazenil 1.0 mg, (b) midazolam 10 mg followed after ten minutes by flumazenil 4.0 mg or (c) physiological saline followed ten minutes later by physiological saline as a placebo control. Midazolam injection was made over 10 seconds and flumazenil over 30 seconds. Midazolam 10 mg was diluted to 10 ml in physiological saline and flumazenil was made up to 50 ml with physiological saline in order that corresponding injections were of the same volume and appearance. All compounds were prepared and given by an anaesthetist not involved with the data collection. Each study day was separated by an interval of at least two weeks and all data was recorded by the same investigator who had no prior knowledge of the compounds being given.
Following the initial injection subjects lay supine and at thirty-second intervals were asked to keep their eyes open. The degree of sedation was noted using a seven-point sedation scale (Table 1) recorded immediately following each request. Heart rate, blood pressure ('Dinamap' automatic recorder), respiratory rate and end-tidal carbon dioxide (nasal cannulae with 'Datex' CO 2 analyser) were asked to assess a range of subjective feelings by marking either 10 cm linear analogue bipolar scales or 5 cm linear analogue unipolar scales as appropriate. These scales were derived from Bond and Lader. 4 2. Gross motor co-ordination: involuntary body sway both with eyes open and eyes shut was assessed at each time interval and scored using a scale devised by Vickers. 5 The ability to walk a straight line heel to toe was also assessed using a fivemetre line along which subjects were asked to walk, turn around and walk back again. They were scored according to the number of times the subject stumbled and the degree of sway subjects showed according to a scale devised by Kortilla. fusion frequency was recorded as the mean of six readings taken using alternate ascending or descending flicker frequencies. 5. Tapping test: subjects were asked to tap a button as fast as possible for thirty seconds. The score was taken as the number of times the button was tapped. 6. Ball-bearing test: subjects were asked to pick up ball-bearings from a shallow dish with a pair of tweezers and place them in a test tube as rapidly as possible. The score was taken as the number of ball-bearings successfully placed in thirty seconds minus the number of ball-bearings dropped. 7. Digit-symbol substitution: subjects were asked to substitute Roman alphabet for Russian alphabet characters according to a table. The score was taken as the time taken to complete 16 substitutions. 8. Seven-digit recall: thirty consecutive seven-digit numbers were presented on a microcomputer screen for recall. Each number was shown for four seconds, and after a seven-second interval, subjects entered the memorised number on the keyboard. The digit recall score was taken as the total number of digits correctly recalled out of a possible 210. Because of the complexity of this task, the test was only performed once (apart from the training session) prior to midazolam injection and then at 5, 65, 125 and 185 minutes after. 9. Amnesia: five minutes after flumazenil injection subjects were shown a series of 10 postcards at five-second intervals. Three hours later at the end of the study day subjects were asked to select the ten cards they had seen from a group of 20. A different set of postcards was used for each study day. The simple reflex time, tapping test and seven-digit recall were each performed on an Apple lIe microcomputer.
STATISTICAL ANALYSIS Physiological data and motor co-ordination tests were analysed using a two-way (treatment and time) analysis of variance (ANOY A) for repeated measures.
The psychomotor sedation tests and mood scales were analysed using a two-factor (treatment and time) analysis of covariance for repeated measures (ANCOYA) with the covariate taken as the second of the two pretreatment scores obtained for each test. Between-group comparisons at specific times were made only if an overall between-group level of significance was found equal to, or less than 0.05. RESULTS Following injection of midazolam there was no significant change in blood pressure, respiratory rate or end-tidal CO 2 when compared with placebo. Following both doses of flumazenil there was again no significant change in these indices. Heart rate however increased from a mean of 55 beats per minute to 70 following midazolam and returned to baseline levels within two minutes of flumazenil (both 1.0 mg and 4.0 mg) injection. Figure 1 shows the changes in mean sedation score for the three groups. Mean sedation scores in both midazolam groups increased from 0 to 3.5. Following flumazenil, sedation scores rapidly decreased to 0.67, three minutes after 1.0 mg flumazenil and two minutes after 4.0 mg flumazenil. No subject experienced nausea, sweating, headache or dry mouth after either dose of flumazenil: however, dizziness on standing was present in all subjects after both 4.0 mg (P < 0.001) and 1.0 mg (P < 0.001) flumazenil at five minutes post reversal, but not at any other time.
Data from the LAS mood scales are summarised in Table 2 Because the ten mood scales expressing sedative feelings (drowsy, calm, fuzzy, clumsy, mentally slow, lazy, incapable, dreamy, relaxed and drugged) all followed a similar pattern, they were summed together and averaged for each individual (the sedative mood score). The results to the mean sedative mood are shown in Figure 2 and statistical analysis in Tables 3 and 4 .
The test of involuntary body sway showed no difference between groups when eyes were open; however, a significant difference when Tl me (ml nutes) eyes were shut was found between placebo and flumazenil 1.0 mg lasting 65 minutes while flumazenil4.0 mg was indistinguishable from placebo at all times. Ability to walk heel to toe along a straight line was significantly impaired in both flumazenil groups, the impairment lasting 35 minutes after flumazenil 4.0 mg and 95 minutes after flumazenil 1.0 mg.
Results for the psychomotor test series are shown in Table 4 , which displays the P values for between treatment, repeated measures ANCOV A for each psychomotor test. There were significant between-groups differences for critical flicker fusion (P < 0.001, Figure 3) , digit symbol substitution (P < 0.003, Figure  4 ) and tapping test (P < 0.012). For reflex time, the ball test and seven-digit number recall no overall difference existed between the three groups. Examination of the curves for sedative mood scale, critical flicker fusion frequency and digit symbol substitution demonstrates a deterioration in performance over the first 15-35 minutes following flumazenil 1.0 mg.
Recall for the postcards revealed no significant amnesia immediately following flumazenil, the mean number of cards successfully recalled being 8.2 after 1.0 mg flumazenil, 9.7 after 4.0 mg flumazenil and 9.0 with placebo. ...
U. resedation. In this study we have found that although there is a rapid return towards control levels of psychomotor performance, neither 1 nor 4 mg completely antagonises the psychomotor effects of midazolam 10 mg. Previous volunteer studies have found minimal psychomotor effects due to flumazenil alone 7 ,8 and its ability to reverse benzodiazepine sedation has been clearly demonstrated.
9 .
15 Few studies, however, have critically compared the quality of reversed benzodiazepine sedation against that of a control group that has received neither benzodiazepine sedation nor flumazenil. An exception to this is an early series of volunteer studies by Darragh et al. who examined the ability of both oral 16 and intravenous 17 doses of flumazenil to reverse the sedative effects of oral 3-methyl clonazepam and the ability of oral flumazenil to reverse oral diazepam. IS In each instance, following reversal, no statistical difference from an unsedated placebo control group could be found. The dose of flumazenil used in that series, however, was large (oral 100-200 mg, IV 20 mg) relative to the doses now recommended by the manufacturers for routine clinical use (up to 1 mg IV).
In this present study, flumazenil rapidly antagonised the hypnotic and amnesic effects of midazolam. The increase in flumazenil dose from 1 mg to 4 mg resulted in a better immediate performance and also a shorter total duration of psychomotor deficit. Significant alterations in mood were apparent, however, for approximately 55 minutes after the 4 mg dose of flumazenil and 95 minutes after the 1 mg dose. One or more tests in the psychomotor battery were impaired for periods of up to 65 minutes after 4 mg flumazenil and up to 125 minutes after 1 mg flumazenil. The overall apparent sensitivity of these tests to residual psychomotor impairment appeared to be as follows: mood scale = critical flicker fusion> digit symbol> tapping test> reflex time> ball-bearing test.
We believe the residual deficits observed in this study are of practical significance, particularly when one considers the much smaller deficits in similar psychomotor tests found by Fagan et al. 19 with ethanol in a concentration of 17.4 mmol/l (the British legal driving limit). For day-case benzodiazepine anaesthesia therefore, a patient will not be returned to immediate street fitness with standard doses of flumazenil, a conclusion supported by previous practical experience. 1, 2 Although it is possible that doses offlumazenil greater than those used in this study could return a patient closer to the presedation state, Also of significance for outpatient sedation was the deterioration in performance observed after the 1 mg dose over the first 35 minutes after its administration. This effect is presumed to be occurring within the rapid distribution phase of flumazenil and is likely to be more apparent with higher ratios of midazolam to flumazenil dose. A practical implication of this resedation is that after reversal of midazolam, a patient should not be immediately discharged from hospital.
In conclusion, intravenous doses of flumazenil up to 4 mg do not completely antagonise the effects of intravenous midazolam 10 mg, given 10 minutes previously. While the reasons for this incomplete reversal are not known with certainty, our results imply that caution should be exercised when discharging patients after antagonised benzodiazepine sedation and in particular patients should not be discharged within thirty minutes of reversal.
